Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | PALOMA-3 results: subcutaneous amivantamab + lazertinib in NSCLC could replace IV formulation

Natasha Leighl, MD, FASCO, Princess Margaret Cancer Centre, Toronto, Canada, discusses the Phase III PALOMA-3 (NCT05388669) results, which she hopes will lead to the registration and approval of the subcutaneous formulation of amivantamab in combination with lazertinib in non-small cell lung cancer (NSCLC). This advancement could replace all current intravenous (IV) indications of amivantamab for patients. The benefits include reduced hospital time, less disruption to patients’ lives, fewer infusion-related reactions, and a lower incidence of blood clots. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.